Literature DB >> 21171937

Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study.

Kazuyoshi Shigehara1, Kazuhiro Sugimoto, Hiroyuki Konaka, Masashi Iijima, Masato Fukushima, Yuji Maeda, Atsushi Mizokami, Eitetsu Koh, Hideki Origasa, Teruaki Iwamoto, Mikio Namiki.   

Abstract

PURPOSE: We performed a randomised controlled study regarding the effects of androgen replacement therapy (ART) on lower urinary tract symptoms (LUTS) in hypogonadal men with benign prostate hypertrophy (BPH).
METHODS: Fifty-two patients with hypogonadism and BPH were randomly assigned to receive testosterone (ART group) as 250 mg of testosterone enanthate every 4 weeks or to the untreated control group. We compared International Prostate Symptom Score (IPSS), uroflowmetry data, post-voiding residual volume (PVR) and systemic muscle volume at baseline and 12 months after treatment.
RESULTS: Forty-six patients (ART group, n=23; control, n=23) were included in the analysis. At the 12-month visit, IPSS showed a significant decrease compared with baseline in the ART group (15.7 +/- 8.7 vs. 12.5 +/- 9.5; p<0.05). No significant changes were observed in the control group. The ART group also showed improvement in maximum flow rate and voided volume (p<0.05), whereas no significant improvements were observed in the controls. PVR showed no significant changes in either group. In addition, the ART group showed significant enhancement of mean muscle volume (p<0.05), whereas no significant changes were seen in the controls.
CONCLUSION: ART improved LUTS in hypogonadal men with mild BPH.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21171937     DOI: 10.3109/13685538.2010.518178

Source DB:  PubMed          Journal:  Aging Male        ISSN: 1368-5538            Impact factor:   5.892


  34 in total

Review 1.  Adverse effects of testosterone replacement therapy: an update on the evidence and controversy.

Authors:  Anthony Grech; John Breck; Joel Heidelbaugh
Journal:  Ther Adv Drug Saf       Date:  2014-10

Review 2.  The treatment of late-onset hypogonadism.

Authors:  Oktay Üçer; Bilal Gümüş
Journal:  Turk J Urol       Date:  2014-03-24

Review 3.  Benign prostatic hyperplasia: a new metabolic disease?

Authors:  L Vignozzi; G Rastrelli; G Corona; M Gacci; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2014-01-24       Impact factor: 4.256

Review 4.  Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome.

Authors:  Linda Vignozzi; Mauro Gacci; Mario Maggi
Journal:  Nat Rev Urol       Date:  2016-01-12       Impact factor: 14.432

Review 5.  Testosterone deficiency and replacement: Myths and realities.

Authors:  Ethan D Grober
Journal:  Can Urol Assoc J       Date:  2014-07       Impact factor: 1.862

Review 6.  Testosterone Replacement Therapy on the Natural History of Prostate Disease.

Authors:  Aaron Moore; Michael J Butcher; Tobias S Köhler
Journal:  Curr Urol Rep       Date:  2015-08       Impact factor: 3.092

7.  Testosterone replacement therapy and prostate health.

Authors:  A Scott Polackwich; Kevin A Ostrowski; Jason C Hedges
Journal:  Curr Urol Rep       Date:  2012-12       Impact factor: 3.092

8.  Erectile function and late-onset hypogonadism symptoms related to lower urinary tract symptom severity in elderly men.

Authors:  Ozan Bozkurt; Deniz Bolat; Omer Demir; Oktay Ucer; Ali Sahin; Burak Ozcift; Abdulkadir Pektaş; Tahir Turan; Bilal H Gümüş; Ertan Can; Ahmet Bolukbasi; Haluk Erol; Adil Esen
Journal:  Asian J Androl       Date:  2013-07-01       Impact factor: 3.285

Review 9.  Benefits and Consequences of Testosterone Replacement Therapy: A Review.

Authors:  Polackwich As; Tadros Nn; Ostrowski Ka; Hedges Jc
Journal:  Eur Endocrinol       Date:  2013-03-15

10.  Effects of Testosterone on Benign and Malignant Conditions of the Prostate.

Authors:  Amin S Herati; Taylor P Kohn; Peter R Butler; Larry I Lipshultz
Journal:  Curr Sex Health Rep       Date:  2017-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.